Array BioPharma Inc. (ARRY) said that the Gynecologic Oncology Group presented results of a Phase 2 trial with selumetinib, a small-molecule MEK inhibitor, in women with recurrent low-grade serous ovarian or peritoneal cancer. Selumetinib was invented by Array BioPharma and licensed to AstraZeneca (AZN, AZN.L).
The Gynecological Oncology Group revealed a disease control rate, defined as either complete or partial response or progression-free survival or progression-free survival of greater than 6 months, of 81% of patients. Eight patients had complete or partial responses, and 34 had progression-free survival of greater than 6 months. The median survival rate without cancer progression was 11 months.
In the reported trial, 52 women each received 100-mg doses of selumetinib orally twice daily in four-week cycles until disease progression or toxicity. Prior to the trial, 58% of the patients in the trial had received three or more rounds of chemotherapy.
Array anticipates top-line results for the Phase 2 trial with selumetinib in combination with dacarbazine versus dacarbazine alone as first-line treatment in patients with BRAF-mutant melanoma to be reported in 2012. In addition, Array expects that further data and analyses will be presented in the second quarter of 2012 for the randomized Phase 2 trial conducted by AstraZeneca comparing selumetinib in combination with docetaxel versus docetaxel alone in the second-line treatment of patients prospectively selected with KRAS-mutant, locally advanced or metastatic, non-small cell lung cancer.
For comments and feedback: editorial@rttnews.com